10-K: Palisade Bio Reports 2024 Results, Cautions on Going Concern

Palisade Bio's 10-K filing reveals ongoing net losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate PALI-2108.

Summary

• Palisade Bio, a clinical-stage biopharmaceutical company, filed its 10-K report for the year ended December 31, 2024.
• The company is focused on developing PALI-2108 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn's disease (FSCD).
• A Phase 1 clinical trial of PALI-2108 is underway in Canada, with topline data expected in the second quarter of 2025.
• The company anticipates filing an Investigational New Drug Application (IND) with the FDA in 2025 and commencing clinical trials in the U.S. in the first quarter of 2026, pending IND approval.
• Palisade Bio reported an operating loss of approximately $14.9 million for 2024, with research and development expenses of $9.1 million and general and administrative expenses of $5.8 million.
• Net cash used in operating activities was approximately $12.2 million for the year ended December 31, 2024.
• The company completed several financings in 2024, including an underwritten public offering in December for net cash proceeds of $4.1 million, a private placement in May for $3.5 million, and a warrant inducement transaction in February for $2.2 million.
• As of December 31, 2024, Palisade Bio had $9.8 million in cash and cash equivalents, which is expected to fund operations through the fourth quarter of 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months, requiring additional financing to sustain operations.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there is progress in clinical development, the going concern warning and financial losses weigh heavily, resulting in a negative sentiment.

Positives

• Phase 1 clinical trial of PALI-2108 is underway in Canada, with topline data expected in the second quarter of 2025.
• The company has two qualified suppliers for the active pharmaceutical ingredient (API) used in PALI-2108.
• The company has a research collaboration and license agreement with Giiant Pharma Inc. for PALI-2108.
• The company has a co-development and distribution agreement with Newsoara for LB1148 in China.

Negatives

• The company has a limited operating history and has never generated any revenues from product sales.
• The company has a history of net operating losses, and expects to continue to incur net operating losses and may never achieve profitability.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company has a material weakness in internal controls over financial reporting.
• The company is dependent on third parties for the supply and manufacture of PALI-2108.
• The company may find it difficult to enroll patients in its clinical trials, which could delay or prevent it from proceeding with clinical trials of its product candidates.

Risks

• The company's business depends on the successful clinical development, regulatory approval, and commercialization of its therapeutic compounds, including its lead asset PALI-2108.
• There are substantial risks in drug development, and, as a result, the company may not be able to successfully develop any product candidate, including its lead product candidate, PALI-2108.
• The company depends on its license agreement with Giiant to permit it to use patents and patent applications relating to PALI-2108. Termination of these rights or the failure to comply with its obligations under the license agreement could materially harm its business and prevent it from developing or commercializing PALI-2108, its lead product candidate.
• The company expects that its operations and development of PALI-2108 will require substantially more capital than it currently has, and it cannot guarantee when or if it will be able to secure such additional funding.
• The company's common stock price may be highly volatile.
• The company's common stock could be delisted from the Nasdaq Stock Market if it is unable to maintain compliance with the Nasdaq Stock Market's continued listing standards.

Future Outlook

The company expects to continue to incur operating losses for the foreseeable future and will need to raise additional capital to fund its operations. Topline data from the Phase 1 clinical trial of PALI-2108 is expected in the second quarter of 2025. The company plans to initiate a Phase 1b/2a clinical study in UC patients in the first quarter of 2026, pending trial results. The company anticipates commencing clinical trials of PALI-2108 in the United States (U.S.) during the first quarter of 2026, pending IND approval.

Management Comments

• Management has determined that there is substantial doubt about our ability to continue as a going concern for a period of one year following the issuance of this Annual Report on Form 10-K.
• Based on our cash and cash equivalents balance of $9.8 million as of December 31, 2024, we believe we have sufficient cash to fund our currently planned operations through the fourth quarter of 2025.

Industry Context

The company operates in the competitive biopharmaceutical industry, facing competition from both small and large companies with greater resources. The company's focus on PDE4 inhibitor prodrugs and precision medicine for IBD presents both opportunities and challenges.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To assess the results in the context of global benchmarks, specific comparable companies, projects, and results would need to be identified.
• Without this information, it is difficult to determine how Palisade Bio's performance compares to its peers.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity sales.
• Employees face uncertainty due to the company's going concern status and potential for operational changes.
• Patients may benefit from the development of PALI-2108, if approved.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Announce topline data from the Phase 1 clinical trial of PALI-2108 during the second quarter of 2025.
• Initiate a Phase 1b/2a clinical study in UC patients in the first quarter of 2026, pending trial results.
• File an Investigational New Drug Application (IND) with the FDA in 2025.
• Commence clinical trials of PALI-2108 in the United States (U.S.) during the first quarter of 2026, pending IND approval.
• Secure additional funding to sustain operations beyond the fourth quarter of 2025.

Key Dates

Keywords

PALI-2108, inflammatory bowel disease, ulcerative colitis, Fibrostenotic Crohn's disease, clinical trial, biopharmaceutical, FDA, Giiant, Newsoara, LB1148, financing, going concern